The global market for CAR-T Therapy For B-Cell Malignancies was valued at US$ 3120 million in the year 2024 and is projected to reach a revised size of US$ 8189 million by 2031, growing at a CAGR of 14.8% during the forecast period.

CAR-T Therapy For B-Cell Malignancies Market

Chimeric antigen receptor T (CAR-T) cell therapy is an individualized immunotherapy method that uses genetic engineering technology to modify the patient's own T cells to express chimeric antigen receptors (CAR) that can recognize specific antigens on the surface of cancer cells, thereby accurately killing tumor cells. In B-cell malignancies such as B-cell lymphoma, acute lymphoblastic leukemia, multiple myeloma, etc., CAR-T therapy mainly targets B-cell surface antigens (such as CD19, CD20, BCMA) and has become an important treatment option for recurrent or refractory patients.

In recent years, the market size of CAR-T therapy for B-cell malignancies has been continuously expanding. The main driving factors of the market include the increase of the incidence rate of B cell malignant tumors, the progress of related technologies (such as genetic engineering technology, cell production technology, drug delivery system), and the policy support of governments of various countries. The main participants in the market include internationally renowned companies such as Gilead, Roche, Novartis, as well as domestic companies such as Fosun Kite Bio, JW Therapeutics, and CARsgen Therapeutics. These companies are continuously increasing their R&D investment and developing innovative CAR-T therapies to meet clinical needs. The research on CAR-T therapy in B-cell malignancies mainly focuses on improving efficacy and prolonging patient survival. The main bottlenecks in the market are high treatment costs, complex preparation processes, potential side effects, indications limitations, and supply chain issues. The future trend of the industry is the research and development of universal CAR-T, the expansion of application areas (especially in the field of solid tumors), and more policy support. Enterprises will focus on improving the accessibility and safety of CAR-T therapy, developing new target antigens, and promoting the development of combination therapies. In addition, advances in gene editing technology may also bring new opportunities for CAR-T therapy. With the approval of more CAR-T products and the accumulation of clinical data, the CAR-T therapy market for B-cell malignancies is expected to continue to grow in the coming years.

This report aims to provide a comprehensive presentation of the global market for CAR-T Therapy For B-Cell Malignancies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR-T Therapy For B-Cell Malignancies.

The CAR-T Therapy For B-Cell Malignancies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global CAR-T Therapy For B-Cell Malignancies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the CAR-T Therapy For B-Cell Malignancies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of CAR-T Therapy For B-Cell Malignancies Market Report

Report Metric	Details
Report Name	CAR-T Therapy For B-Cell Malignancies Market
Accounted market size in year	US$ 3120 million
Forecasted market size in 2031	US$ 8189 million
CAGR	14.8%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Single Target CAR-T Dual Targets CAR-T Multi Targets CAR-T Universal CAR-T Gene Modified Enhanced CAR-T
Segment by Application	B-Cell Acute Lymphoblastic Leukemia B-Cell Non-Hodgkin's Lymphoma Multiple Myeloma Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Gilead Sciences, Roche, Novartis, Regeneron Pharmaceuticals, Bristol Myers Squibb, Celgene, Johnson And Johnson, Bluebird Bio, Kite Pharma, AstraZeneca, Fosun Kite Bio, JW Therapeutics, CARsgen Therapeutics, IMCURE, HEBECELL, Legend Biotech, Beihai Biotechnology, Chongqing Precision Biotech
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR-T Therapy For B-Cell Malignancies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is CAR-T Therapy For B-Cell Malignancies Market growing?

Ans: The CAR-T Therapy For B-Cell Malignancies Market witnessing a CAGR of 14.8% during the forecast period 2025-2031.

What is the CAR-T Therapy For B-Cell Malignancies Market size in 2031?

Ans: The CAR-T Therapy For B-Cell Malignancies Market size in 2031 will be US$ 8189 million.

Who are the main players in the CAR-T Therapy For B-Cell Malignancies Market report?

Ans: The main players in the CAR-T Therapy For B-Cell Malignancies Market are Gilead Sciences, Roche, Novartis, Regeneron Pharmaceuticals, Bristol Myers Squibb, Celgene, Johnson And Johnson, Bluebird Bio, Kite Pharma, AstraZeneca, Fosun Kite Bio, JW Therapeutics, CARsgen Therapeutics, IMCURE, HEBECELL, Legend Biotech, Beihai Biotechnology, Chongqing Precision Biotech

What are the Application segmentation covered in the CAR-T Therapy For B-Cell Malignancies Market report?

Ans: The Applications covered in the CAR-T Therapy For B-Cell Malignancies Market report are B-Cell Acute Lymphoblastic Leukemia, B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, Others

What are the Type segmentation covered in the CAR-T Therapy For B-Cell Malignancies Market report?

Ans: The Types covered in the CAR-T Therapy For B-Cell Malignancies Market report are Single Target CAR-T, Dual Targets CAR-T, Multi Targets CAR-T, Universal CAR-T, Gene Modified Enhanced CAR-T

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Single Target CAR-T

1.2.3 Dual Targets CAR-T

1.2.4 Multi Targets CAR-T

1.2.5 Universal CAR-T

1.2.6 Gene Modified Enhanced CAR-T

1.3 Market by Application

1.3.1 Global CAR-T Therapy For B-Cell Malignancies Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 B-Cell Acute Lymphoblastic Leukemia

1.3.3 B-Cell Non-Hodgkin's Lymphoma

1.3.4 Multiple Myeloma

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global CAR-T Therapy For B-Cell Malignancies Market Perspective (2020-2031)

2.2 Global CAR-T Therapy For B-Cell Malignancies Growth Trends by Region

2.2.1 Global CAR-T Therapy For B-Cell Malignancies Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 CAR-T Therapy For B-Cell Malignancies Historic Market Size by Region (2020-2025)

2.2.3 CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Region (2026-2031)

2.3 CAR-T Therapy For B-Cell Malignancies Market Dynamics

2.3.1 CAR-T Therapy For B-Cell Malignancies Industry Trends

2.3.2 CAR-T Therapy For B-Cell Malignancies Market Drivers

2.3.3 CAR-T Therapy For B-Cell Malignancies Market Challenges

2.3.4 CAR-T Therapy For B-Cell Malignancies Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top CAR-T Therapy For B-Cell Malignancies Players by Revenue

3.1.1 Global Top CAR-T Therapy For B-Cell Malignancies Players by Revenue (2020-2025)

3.1.2 Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Players (2020-2025)

3.2 Global Top CAR-T Therapy For B-Cell Malignancies Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by CAR-T Therapy For B-Cell Malignancies Revenue

3.4 Global CAR-T Therapy For B-Cell Malignancies Market Concentration Ratio

3.4.1 Global CAR-T Therapy For B-Cell Malignancies Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by CAR-T Therapy For B-Cell Malignancies Revenue in 2024

3.5 Global Key Players of CAR-T Therapy For B-Cell Malignancies Head office and Area Served

3.6 Global Key Players of CAR-T Therapy For B-Cell Malignancies, Product and Application

3.7 Global Key Players of CAR-T Therapy For B-Cell Malignancies, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 CAR-T Therapy For B-Cell Malignancies Breakdown Data by Type

4.1 Global CAR-T Therapy For B-Cell Malignancies Historic Market Size by Type (2020-2025)

4.2 Global CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Type (2026-2031)

5 CAR-T Therapy For B-Cell Malignancies Breakdown Data by Application

5.1 Global CAR-T Therapy For B-Cell Malignancies Historic Market Size by Application (2020-2025)

5.2 Global CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America CAR-T Therapy For B-Cell Malignancies Market Size (2020-2031)

6.2 North America CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025)

6.4 North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe CAR-T Therapy For B-Cell Malignancies Market Size (2020-2031)

7.2 Europe CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025)

7.4 Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size (2020-2031)

8.2 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size by Region (2020-2025)

8.4 Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America CAR-T Therapy For B-Cell Malignancies Market Size (2020-2031)

9.2 Latin America CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025)

9.4 Latin America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size (2020-2031)

10.2 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025)

10.4 Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Gilead Sciences

11.1.1 Gilead Sciences Company Details

11.1.2 Gilead Sciences Business Overview

11.1.3 Gilead Sciences CAR-T Therapy For B-Cell Malignancies Introduction

11.1.4 Gilead Sciences Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.1.5 Gilead Sciences Recent Development

11.2 Roche

11.2.1 Roche Company Details

11.2.2 Roche Business Overview

11.2.3 Roche CAR-T Therapy For B-Cell Malignancies Introduction

11.2.4 Roche Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.2.5 Roche Recent Development

11.3 Novartis

11.3.1 Novartis Company Details

11.3.2 Novartis Business Overview

11.3.3 Novartis CAR-T Therapy For B-Cell Malignancies Introduction

11.3.4 Novartis Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.3.5 Novartis Recent Development

11.4 Regeneron Pharmaceuticals

11.4.1 Regeneron Pharmaceuticals Company Details

11.4.2 Regeneron Pharmaceuticals Business Overview

11.4.3 Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Introduction

11.4.4 Regeneron Pharmaceuticals Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.4.5 Regeneron Pharmaceuticals Recent Development

11.5 Bristol Myers Squibb

11.5.1 Bristol Myers Squibb Company Details

11.5.2 Bristol Myers Squibb Business Overview

11.5.3 Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Introduction

11.5.4 Bristol Myers Squibb Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.5.5 Bristol Myers Squibb Recent Development

11.6 Celgene

11.6.1 Celgene Company Details

11.6.2 Celgene Business Overview

11.6.3 Celgene CAR-T Therapy For B-Cell Malignancies Introduction

11.6.4 Celgene Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.6.5 Celgene Recent Development

11.7 Johnson And Johnson

11.7.1 Johnson And Johnson Company Details

11.7.2 Johnson And Johnson Business Overview

11.7.3 Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Introduction

11.7.4 Johnson And Johnson Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.7.5 Johnson And Johnson Recent Development

11.8 Bluebird Bio

11.8.1 Bluebird Bio Company Details

11.8.2 Bluebird Bio Business Overview

11.8.3 Bluebird Bio CAR-T Therapy For B-Cell Malignancies Introduction

11.8.4 Bluebird Bio Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.8.5 Bluebird Bio Recent Development

11.9 Kite Pharma

11.9.1 Kite Pharma Company Details

11.9.2 Kite Pharma Business Overview

11.9.3 Kite Pharma CAR-T Therapy For B-Cell Malignancies Introduction

11.9.4 Kite Pharma Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.9.5 Kite Pharma Recent Development

11.10 AstraZeneca

11.10.1 AstraZeneca Company Details

11.10.2 AstraZeneca Business Overview

11.10.3 AstraZeneca CAR-T Therapy For B-Cell Malignancies Introduction

11.10.4 AstraZeneca Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.10.5 AstraZeneca Recent Development

11.11 Fosun Kite Bio

11.11.1 Fosun Kite Bio Company Details

11.11.2 Fosun Kite Bio Business Overview

11.11.3 Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Introduction

11.11.4 Fosun Kite Bio Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.11.5 Fosun Kite Bio Recent Development

11.12 JW Therapeutics

11.12.1 JW Therapeutics Company Details

11.12.2 JW Therapeutics Business Overview

11.12.3 JW Therapeutics CAR-T Therapy For B-Cell Malignancies Introduction

11.12.4 JW Therapeutics Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.12.5 JW Therapeutics Recent Development

11.13 CARsgen Therapeutics

11.13.1 CARsgen Therapeutics Company Details

11.13.2 CARsgen Therapeutics Business Overview

11.13.3 CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Introduction

11.13.4 CARsgen Therapeutics Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.13.5 CARsgen Therapeutics Recent Development

11.14 IMCURE

11.14.1 IMCURE Company Details

11.14.2 IMCURE Business Overview

11.14.3 IMCURE CAR-T Therapy For B-Cell Malignancies Introduction

11.14.4 IMCURE Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.14.5 IMCURE Recent Development

11.15 HEBECELL

11.15.1 HEBECELL Company Details

11.15.2 HEBECELL Business Overview

11.15.3 HEBECELL CAR-T Therapy For B-Cell Malignancies Introduction

11.15.4 HEBECELL Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.15.5 HEBECELL Recent Development

11.16 Legend Biotech

11.16.1 Legend Biotech Company Details

11.16.2 Legend Biotech Business Overview

11.16.3 Legend Biotech CAR-T Therapy For B-Cell Malignancies Introduction

11.16.4 Legend Biotech Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.16.5 Legend Biotech Recent Development

11.17 Beihai Biotechnology

11.17.1 Beihai Biotechnology Company Details

11.17.2 Beihai Biotechnology Business Overview

11.17.3 Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Introduction

11.17.4 Beihai Biotechnology Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.17.5 Beihai Biotechnology Recent Development

11.18 Chongqing Precision Biotech

11.18.1 Chongqing Precision Biotech Company Details

11.18.2 Chongqing Precision Biotech Business Overview

11.18.3 Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Introduction

11.18.4 Chongqing Precision Biotech Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

11.18.5 Chongqing Precision Biotech Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Gilead Sciences

Roche

Novartis

Regeneron Pharmaceuticals

Chongqing Precision Biotech

List of Tables

Table 1. Global CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Single Target CAR-T

Table 3. Key Players of Dual Targets CAR-T

Table 4. Key Players of Multi Targets CAR-T

Table 5. Key Players of Universal CAR-T

Table 6. Key Players of Gene Modified Enhanced CAR-T

Table 7. Global CAR-T Therapy For B-Cell Malignancies Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 8. Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global CAR-T Therapy For B-Cell Malignancies Market Size by Region (2020-2025) & (US$ Million)

Table 10. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region (2020-2025)

Table 11. Global CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 12. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region (2026-2031)

Table 13. CAR-T Therapy For B-Cell Malignancies Market Trends

Table 14. CAR-T Therapy For B-Cell Malignancies Market Drivers

Table 15. CAR-T Therapy For B-Cell Malignancies Market Challenges

Table 16. CAR-T Therapy For B-Cell Malignancies Market Restraints

Table 17. Global CAR-T Therapy For B-Cell Malignancies Revenue by Players (2020-2025) & (US$ Million)

Table 18. Global CAR-T Therapy For B-Cell Malignancies Market Share by Players (2020-2025)

Table 19. Global Top CAR-T Therapy For B-Cell Malignancies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in CAR-T Therapy For B-Cell Malignancies as of 2024)

Table 20. Ranking of Global Top CAR-T Therapy For B-Cell Malignancies Companies by Revenue (US$ Million) in 2024

Table 21. Global 5 Largest Players Market Share by CAR-T Therapy For B-Cell Malignancies Revenue (CR5 and HHI) & (2020-2025)

Table 22. Global Key Players of CAR-T Therapy For B-Cell Malignancies, Headquarters and Area Served

Table 23. Global Key Players of CAR-T Therapy For B-Cell Malignancies, Product and Application

Table 24. Global Key Players of CAR-T Therapy For B-Cell Malignancies, Date of Enter into This Industry

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global CAR-T Therapy For B-Cell Malignancies Market Size by Type (2020-2025) & (US$ Million)

Table 27. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Type (2020-2025)

Table 28. Global CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 29. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Type (2026-2031)

Table 30. Global CAR-T Therapy For B-Cell Malignancies Market Size by Application (2020-2025) & (US$ Million)

Table 31. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Application (2020-2025)

Table 32. Global CAR-T Therapy For B-Cell Malignancies Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 33. Global CAR-T Therapy For B-Cell Malignancies Revenue Market Share by Application (2026-2031)

Table 34. North America CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025) & (US$ Million)

Table 36. North America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031) & (US$ Million)

Table 37. Europe CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 38. Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025) & (US$ Million)

Table 39. Europe CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031) & (US$ Million)

Table 40. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 41. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size by Region (2020-2025) & (US$ Million)

Table 42. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size by Region (2026-2031) & (US$ Million)

Table 43. Latin America CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Latin America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025) & (US$ Million)

Table 45. Latin America CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031) & (US$ Million)

Table 46. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2020-2025) & (US$ Million)

Table 48. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size by Country (2026-2031) & (US$ Million)

Table 49. Gilead Sciences Company Details

Table 50. Gilead Sciences Business Overview

Table 51. Gilead Sciences CAR-T Therapy For B-Cell Malignancies Product

Table 52. Gilead Sciences Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 53. Gilead Sciences Recent Development

Table 54. Roche Company Details

Table 55. Roche Business Overview

Table 56. Roche CAR-T Therapy For B-Cell Malignancies Product

Table 57. Roche Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 58. Roche Recent Development

Table 59. Novartis Company Details

Table 60. Novartis Business Overview

Table 61. Novartis CAR-T Therapy For B-Cell Malignancies Product

Table 62. Novartis Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 63. Novartis Recent Development

Table 64. Regeneron Pharmaceuticals Company Details

Table 65. Regeneron Pharmaceuticals Business Overview

Table 66. Regeneron Pharmaceuticals CAR-T Therapy For B-Cell Malignancies Product

Table 67. Regeneron Pharmaceuticals Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 68. Regeneron Pharmaceuticals Recent Development

Table 69. Bristol Myers Squibb Company Details

Table 70. Bristol Myers Squibb Business Overview

Table 71. Bristol Myers Squibb CAR-T Therapy For B-Cell Malignancies Product

Table 72. Bristol Myers Squibb Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 73. Bristol Myers Squibb Recent Development

Table 74. Celgene Company Details

Table 75. Celgene Business Overview

Table 76. Celgene CAR-T Therapy For B-Cell Malignancies Product

Table 77. Celgene Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 78. Celgene Recent Development

Table 79. Johnson And Johnson Company Details

Table 80. Johnson And Johnson Business Overview

Table 81. Johnson And Johnson CAR-T Therapy For B-Cell Malignancies Product

Table 82. Johnson And Johnson Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 83. Johnson And Johnson Recent Development

Table 84. Bluebird Bio Company Details

Table 85. Bluebird Bio Business Overview

Table 86. Bluebird Bio CAR-T Therapy For B-Cell Malignancies Product

Table 87. Bluebird Bio Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 88. Bluebird Bio Recent Development

Table 89. Kite Pharma Company Details

Table 90. Kite Pharma Business Overview

Table 91. Kite Pharma CAR-T Therapy For B-Cell Malignancies Product

Table 92. Kite Pharma Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 93. Kite Pharma Recent Development

Table 94. AstraZeneca Company Details

Table 95. AstraZeneca Business Overview

Table 96. AstraZeneca CAR-T Therapy For B-Cell Malignancies Product

Table 97. AstraZeneca Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 98. AstraZeneca Recent Development

Table 99. Fosun Kite Bio Company Details

Table 100. Fosun Kite Bio Business Overview

Table 101. Fosun Kite Bio CAR-T Therapy For B-Cell Malignancies Product

Table 102. Fosun Kite Bio Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 103. Fosun Kite Bio Recent Development

Table 104. JW Therapeutics Company Details

Table 105. JW Therapeutics Business Overview

Table 106. JW Therapeutics CAR-T Therapy For B-Cell Malignancies Product

Table 107. JW Therapeutics Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 108. JW Therapeutics Recent Development

Table 109. CARsgen Therapeutics Company Details

Table 110. CARsgen Therapeutics Business Overview

Table 111. CARsgen Therapeutics CAR-T Therapy For B-Cell Malignancies Product

Table 112. CARsgen Therapeutics Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 113. CARsgen Therapeutics Recent Development

Table 114. IMCURE Company Details

Table 115. IMCURE Business Overview

Table 116. IMCURE CAR-T Therapy For B-Cell Malignancies Product

Table 117. IMCURE Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 118. IMCURE Recent Development

Table 119. HEBECELL Company Details

Table 120. HEBECELL Business Overview

Table 121. HEBECELL CAR-T Therapy For B-Cell Malignancies Product

Table 122. HEBECELL Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 123. HEBECELL Recent Development

Table 124. Legend Biotech Company Details

Table 125. Legend Biotech Business Overview

Table 126. Legend Biotech CAR-T Therapy For B-Cell Malignancies Product

Table 127. Legend Biotech Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 128. Legend Biotech Recent Development

Table 129. Beihai Biotechnology Company Details

Table 130. Beihai Biotechnology Business Overview

Table 131. Beihai Biotechnology CAR-T Therapy For B-Cell Malignancies Product

Table 132. Beihai Biotechnology Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 133. Beihai Biotechnology Recent Development

Table 134. Chongqing Precision Biotech Company Details

Table 135. Chongqing Precision Biotech Business Overview

Table 136. Chongqing Precision Biotech CAR-T Therapy For B-Cell Malignancies Product

Table 137. Chongqing Precision Biotech Revenue in CAR-T Therapy For B-Cell Malignancies Business (2020-2025) & (US$ Million)

Table 138. Chongqing Precision Biotech Recent Development

Table 139. Research Programs/Design for This Report

Table 140. Key Data Information from Secondary Sources

Table 141. Key Data Information from Primary Sources

Table 142. Authors List of This Report

List of Figures

Figure 1. CAR-T Therapy For B-Cell Malignancies Picture

Figure 2. Global CAR-T Therapy For B-Cell Malignancies Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global CAR-T Therapy For B-Cell Malignancies Market Share by Type: 2024 VS 2031

Figure 4. Single Target CAR-T Features

Figure 5. Dual Targets CAR-T Features

Figure 6. Multi Targets CAR-T Features

Figure 7. Universal CAR-T Features

Figure 8. Gene Modified Enhanced CAR-T Features

Figure 9. Global CAR-T Therapy For B-Cell Malignancies Market Size by Application (2020-2031) & (US$ Million)

Figure 10. Global CAR-T Therapy For B-Cell Malignancies Market Share by Application: 2024 VS 2031

Figure 11. B-Cell Acute Lymphoblastic Leukemia Case Studies

Figure 12. B-Cell Non-Hodgkin's Lymphoma Case Studies

Figure 13. Multiple Myeloma Case Studies

Figure 14. Others Case Studies

Figure 15. CAR-T Therapy For B-Cell Malignancies Report Years Considered

Figure 16. Global CAR-T Therapy For B-Cell Malignancies Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 17. Global CAR-T Therapy For B-Cell Malignancies Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 18. Global CAR-T Therapy For B-Cell Malignancies Market Share by Region: 2024 VS 2031

Figure 19. Global CAR-T Therapy For B-Cell Malignancies Market Share by Players in 2024

Figure 20. Global CAR-T Therapy For B-Cell Malignancies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 21. The Top 10 and 5 Players Market Share by CAR-T Therapy For B-Cell Malignancies Revenue in 2024

Figure 22. North America CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. North America CAR-T Therapy For B-Cell Malignancies Market Share by Country (2020-2031)

Figure 24. United States CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Canada CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Europe CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe CAR-T Therapy For B-Cell Malignancies Market Share by Country (2020-2031)

Figure 28. Germany CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. France CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. U.K. CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Italy CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Russia CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Nordic Countries CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific CAR-T Therapy For B-Cell Malignancies Market Share by Region (2020-2031)

Figure 36. China CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Japan CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. South Korea CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Southeast Asia CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. India CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Australia CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Latin America CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America CAR-T Therapy For B-Cell Malignancies Market Share by Country (2020-2031)

Figure 44. Mexico CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Brazil CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa CAR-T Therapy For B-Cell Malignancies Market Share by Country (2020-2031)

Figure 48. Turkey CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Saudi Arabia CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. UAE CAR-T Therapy For B-Cell Malignancies Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Gilead Sciences Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 52. Roche Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 53. Novartis Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 54. Regeneron Pharmaceuticals Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 55. Bristol Myers Squibb Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 56. Celgene Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 57. Johnson And Johnson Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 58. Bluebird Bio Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 59. Kite Pharma Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 60. AstraZeneca Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 61. Fosun Kite Bio Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 62. JW Therapeutics Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 63. CARsgen Therapeutics Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 64. IMCURE Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 65. HEBECELL Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 66. Legend Biotech Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 67. Beihai Biotechnology Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 68. Chongqing Precision Biotech Revenue Growth Rate in CAR-T Therapy For B-Cell Malignancies Business (2020-2025)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global CAR T Therapy for Hematological Cancer Market Research Report 2024

Global CAR T Cell Service Market Research Report 2024

Global Autologous CAR T Cell Therapy Market Research Report 2024

Global CD19 targeted CAR T Cell Therapy Market Research Report 2024

Global BCMA targeted CAR T Cell Therapy Market Research Report 2025

Global CAR T cell Therapy Drug Market Research Report 2025

Global CAR T Cell Development Service Market Research Report 2024

CAR T Cellular Immunotherapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

CAR T Cell Based Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Drug based on CAR T Cell Market Research Report 2025

Global CAR T Cell Therapy Agents Market Research Report 2025

Cancer Drug based on CAR T Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Drugs Based on CAR T cell Market Research Report 2025

Global CAR T Cell Manufacturing Service Market Research Report 2024

Global CAR M Cell Therapy Market Research Report 2025

Global CAR T Cell Immunotherapy Market Insights Forecast to 2030

Global T Cell Immunotherapy Market Research Report 2025

Global Multi Target CAR T Cell Therapy Market Research Report 2025

Global CAR NK Cell Therapy Market Research Report 2025

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions